Title
Lack of efficacy of hydroxychloroquine in covid-19
Date Issued
19 May 2020
Access level
open access
Resource Type
editorial
Author(s)
Yale University School of Medicine
Volume
369
Language
English
OCDE Knowledge area
Inmunología
Epidemiología
Scopus EID
2-s2.0-85084964369
PubMed ID
Source
The BMJ
ISSN of the container
09598146
Sponsor(s)
Funding text
Physicians and patients alike are desperate to use any possible drug for otherwise untreatable covid-19, and there is considerable political pressure as well. Hundreds of clinical trials of potential treatments for covid-19 are now registered on clinicaltrials.gov. While inpatient treatments such as remdesivir, convalescent plasma, and immunomodulators are undergoing formal clinical trials, testing of outpatient treatments lags. The few currently registered trials for outpatients are of interventions including pegylated interferon λ (by single subcutaneous injection), oral favipiravir, and oral camostat mesylate, with clinical and virological outcomes. And, of course, there is hydroxychloroquine, the unproven and probably harmful drug that the US president is currently taking for post-exposure prophylaxis. The largest and most systematic outpatient trial is leveraged by the US National Institutes of Health through its AIDS Clinical Trials Group national network, funded by the National Institute of Allergy and Infectious Diseases. This randomized, placebo controlled, double blind trial includes an estimated 2000 outpatients with early covid-19, testing hydroxychloroquine plus azithromycin versus placebo in preventing hospital admission and death due to covid-19.
Sources of information:
Directorio de Producción Científica
Scopus